CD169 antibody–monomethyl auristatin E

CD169 antibody–monomethyl auristatin E (CD169Ab-MMAE) is an experimental antibody-drug conjugate (ADC) designed to selectively deplete CD169+ (sialoadhesin-positive) macrophages. Developed by researchers at Brigham and Women's Hospital and Harvard Medical School, this therapeutic candidate targets CD169, a cell-surface receptor highly expressed on a distinct subset of bone marrow-derived macrophages that accumulate in chronically rejected cardiac allografts and drive inflammation. The conjugate consists of a monoclonal antibody targeting CD169 linked to the cytotoxic payload monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Upon binding and internalization, MMAE is released, leading to the selective depletion of CD169+ macrophages, which in turn reduces the infiltration of T and B cells, decreases pro-inflammatory cytokine expression, and mitigates chronic transplant rejection.

Other names

CD169 antibody-monomethyl auristatin ECD-169 antibody-monomethyl auristatin ECD 169 antibody-monomethyl auristatin ECD169-MMAECD-169-MMAECD 169-MMAECD169Ab-MMAECD-169Ab-MMAECD 169Ab-MMAE